Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants

Inclusion Criteria: * Chronic HCV infection. * HCV GT-1. * HCV ribonucleic acid \> 10,000 international units/milliliter at screening. * Female participants must be willing to use 2 effective methods of contraception, one of which must be a barrier method, during the dosing period and 6 months after the last dose of RBV. Females of childbearing potential must have a negative pregnancy test at screening and baseline. * Male participants must be willing to use an effective barrier method of contraception throughout the dosing period and for 6 months. * Signed and dated written informed consent form. * Willing to participate in all study activities and all study requirements (including effective contraception) during the study period. * Treatment-naïve participants were defined as those participants who have never received pegylated interferon, RBV, or a direct-acting anti-viral agent for the treatment of chronic HCV infection. * A liver biopsy within the last 3 years without evidence of cirrhosis. Exclusion Criteria: * Body mass index \> 36.0 kilograms/meter squared. * Pregnant or nursing (lactating) female participants confirmed by a positive human chorionic gonadotropin laboratory test or contemplating pregnancy. * Participation in any interventional clinical trial within 35 days prior to first study medication dose administration on Day 1. * Known human immunodeficiency virus (HIV)-1 or HIV-2 infection/serology and/or positive hepatitis B surface antigen. * Use of dietary supplements, grapefruit juice, herbal supplements, cytochrome P450 (CYP) 2C8 substrates, CYP3A4 inducers and inhibitors, P-glycoprotein inducers and substrates, organic-anion-transporting polypeptide inhibitors and substrates, and potent inducers of other CYP enzymes within 14 days prior to dosing through 7 days following completion of study medications. * Clinically significant laboratory abnormality at screening (specified in protocol). * Other forms of liver disease. * History of severe or uncontrolled psychiatric disease. * History of malignancy of any organ system, treated or untreated within the past 5 years. * History of major organ transplantation. * Use of bone marrow colony stimulating factor agents within 3 months prior to baseline. * History of seizure disorder requiring ongoing medical therapy. * History of known coagulopathy including hemophilia. * History of hemoglobinopathy, including sickle cell anemia and thalassemia. * History of immunologically mediated disease (specified in protocol). * History of clinical evidence of significant chronic cardiac disease ( specified in protocol). * Electrocardiogram with any clinically significant abnormality. * Structural or functional cardiac abnormalities (specified in protocol). * History of chronic obstructive pulmonary disease, emphysema, or other chronic lung disease. * Participants currently abusing amphetamines, cocaine or opiates, or with ongoing alcohol abuse in the judgement of the investigator.